首页 >
法规速递
-
Page: Guidance on the application of the revised variations framework-2025/6/30
2025-07-01查看详情 > -
Page: Ursodeoxycholic acid product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Page: Prasugrel product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Page: Paracetamol product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Page: Oseltamivir product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Page: Metformin product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Page: Accessibility-2025/6/30
2025-07-01查看详情 > -
Page: Dabigatran etexilate product-specific bioequivalence guidance-2025/6/30
2025-07-01查看详情 > -
Document: Annual activity report 2024-2025/6/30
2025-07-01查看详情 > -
Page: Real-world evidence-2025/6/30
2025-07-01查看详情 >